• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Expert views
  • Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions

Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions

16 March 2020
Expert views

Webinar Abstract: Diisopropylcarbodiimide (DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma) are the most widely used coupling reagents in peptide synthesis. McFarland et al. recently discovered the reaction  between DIC and Oxyma, which forms hydrogen cyanide (HCN), […]

Diisopropylcarbodiimide (DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma) are the most widely used coupling reagents in peptide synthesis. McFarland et al. recently discovered the reaction  between DIC and Oxyma, which forms hydrogen cyanide (HCN). Controlling the formation of toxic side products is crucial for advancing protocols for safer and environmentally sensible peptide synthesis. HCN is formed during amino acid activation but also during amide bond forming reactions mediated by DIC and Oxyma

Marion Erny, March 16, 2020

Read more

Back to news

Related posts

2 April 2025

Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis


Read more
20 March 2025

Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase


Read more
13 November 2024

Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers